ESMO 2016: News Articles

Interested in what is happening during ESMO 2016? Read our news articles here

Date Title Topic
10 Oct 2016 ESMO 2016: PD-L1 Expression as a Biomarker for Checkpoint Inhibitors Response in Patients with Advanced Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
10 Oct 2016 ESMO 2016: Baseline Genetic Features Elucidated in Responding and Non-Responding Patients with BRAFV600-Mutated Melanoma Translational research - Melanoma and other skin tumours
10 Oct 2016 ESMO 2016: POLE Mutations Identified in Stage II/III Colorectal Cancer as a Biomarker for Favourable Prognosis Translational research - Gastrointestinal cancers
10 Oct 2016 ESMO 2016: ERBB2 Gene Alterations May Be Prognostic of Poorer Outcome in Stage III Colon Cancer Translational research - Gastrointestinal cancers
10 Oct 2016 ESMO 2016: Results of the First Cohort of Patients Screened Within the New EORTC Molecular Platform for Patients With Colorectal Cancer Translational research - Gastrointestinal cancers
09 Oct 2016 ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours Personalised medicine - Anticancer agents & Biologic therapy
09 Oct 2016 ESMO 2016: Triple Combination of Dabrafenib, Trametinib, and Panitumumab Improves Efficacy in BRAF Mutation Positive mCRC Gastrointestinal cancers - Anticancer agents & Biologic therapy
09 Oct 2016 ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung Lung and other thoracic tumours - Anticancer agents & Biologic therapy
09 Oct 2016 ESMO 2016: A Longer Interval Between Preoperative Chemoradiotherapy and Surgery Urged in Locally Advanced Rectal Cancer Gastrointestinal cancers
09 Oct 2016 Lapatinib in HER2-positive digestive tract cancers: Moving on to phase III development?
09 Oct 2016 Shedding light on endocrine therapy sequencing for advanced breast cancer
09 Oct 2016 New kids on the block: ESMO début for novel targeted therapies
09 Oct 2016 Ipilimumab for melanoma: New data show survival benefit in the adjuvant setting and dose–response in metastatic disease
09 Oct 2016 ESMO 2016: Comprehensive Genomic Profiling Identifies Potentially Actionable Mutations in Small Bowel Adenocarcinoma Translational research - Gastrointestinal cancers
08 Oct 2016 ESMO 2016: Factors Identified That Associate with Near the End of Life Chemotherapy Use Palliative and supportive care